Complete baseline imaging assessment of metastatic lesions, including enhanced MRI for brain;
Receiving first-line treatment with third-generation EGFR inhibitors;
After 3-6 months of third-generation EGFR inhibitor treatment, imaging review indicates no progression of extracranial lesions, and brain lesions are evaluated by thin-layer (1mm layer) enhanced MRI, meeting the following criteria:
* No more than 10 remaining brain lesions;
* The maximum diameter of the remaining brain lesions does not exceed 3cm;
* At least one remaining brain lesion has a diameter greater than 5mm;
* After evaluation by the researcher, all remaining brain lesions are suitable for stereotactic radiotherapy.
Patient informed consent.
You may not be if
Poor compliance with the study protocol in the investigator's opinion;
Patients withdrew their informed consent and requested to withdraw from the study;
Patients were unable to receive regular doses of third-generation EGFR inhibitors due to other underlying conditions, viral side effects, economic factors, etc. (e.g., continuous discontinuation for more than 1 week, cumulative discontinuation for more than 2 weeks).
Patients did not follow the protocol for follow-up visits as required by this study.
Clareo Health | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
